Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential non-myeloablative sibling allogeneic stem cell transplantation followed by temsirolimus in TKI-refractory clear-cell renal cell carcinoma
2008-003870-16Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in clear cell renal cell carcinoma (ccRCC) and metastatic renal cell carcinoma (mRCC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Progression-free survival at 6 months after transplantation. Started Jun 2008; status: terminated.
02
Drugs
temsirolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-003870-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003870-16.